Neuropsychiatric assessment of Alzheimer’s disease and related dementias

被引:0
|
作者
J. L. Cummings
S. McPherson
机构
[1] UCLA School of Medicine,Department of Neurology
[2] UCLA School of Medicine,Department Psychiatry and Biobehavioral Science
关键词
Alzheimer’s disease; behavioral alterations; neuropsychiatric assessment; Neuropsychiatric Inventory (NPI); neuropsychological impairment; agitation; psychosis;
D O I
暂无
中图分类号
学科分类号
摘要
Alzheimer’s disease (AD) patients exhibit a variety of behavioral alterations including agitation, apathy, depression, anxiety, delusions, irritability and disinhibition. Most patients with AD exhibit neuropsychiatric symptoms, and behavioral changes become more frequent with advancing disease severity. The NPI is a valid and reliable means of assessing neuropsychiatric symptoms in patients with dementia. The NPI correlates with increasing disability in activities of daily living and increasing cognitive impairment. Physical illness contributes little to behavioral symptoms measured by the NPI. Reduced frontal lobe metabolism and perfusion have been identified in patients with apathy, agitation, psychosis and depression. Patients with elevated agitation scores on the NPI have a higher burden of frontal lobe neurofibrillary tangles than patients without agitation. The NPI is sensitive to behavioral improvements following treatment with cholinesterase inhibitors and psychotropic agents. Neuropsychiatric symptom profiles differ among dementia syndromes, and the NPI provides a means of assessing neuropsychiatric symptoms that may aid in differential diagnosis. Evaluation of neuropsychiatric symptoms is a critical aspect of dementia diagnosis and management.
引用
收藏
页码:240 / 246
页数:6
相关论文
共 50 条
  • [22] Domains of delirium severity in Alzheimer's disease and related dementias
    Schulman-Green, Dena
    Hshieh, Tammy
    Adamis, Dimitrios
    Avidan, Michael S.
    Blazer, Dan G.
    Fick, Donna M.
    Oh, Esther
    Morandi, Alessandro
    Price, Catherine
    Verghese, Joe
    Schmitt, Eva M.
    Jones, Richard N.
    Inouye, Sharon K.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2022, 70 (05) : 1495 - 1503
  • [23] The potential of psychedelics for the treatment of Alzheimer's disease and related dementias
    Winkelman, Michael James
    Szabo, Attila
    Frecska, Ede
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2023, 76 : 3 - 16
  • [24] Recommendations of the Alzheimer's Disease-Related Dementias Conference
    Montine, Thomas J.
    Koroshetz, Walter J.
    Babcock, Debra
    Dickson, Dennis W.
    Galpern, Wendy R.
    Glymour, M. Maria
    Greenberg, Steven M.
    Hutton, Michael L.
    Knopman, David S.
    Kuzmichev, Andrey N.
    Manly, Jennifer J.
    Marder, Karen S.
    Miller, Bruce L.
    Phelps, Creighton H.
    Seeley, William W.
    Sieber, Beth-Anne
    Silverberg, Nina B.
    Sutherland, Margaret
    Torborg, Christine L.
    Waddy, Salina P.
    Zlokovic, Berislav V.
    Corriveau, Roderick A.
    NEUROLOGY, 2014, 83 (09) : 851 - 860
  • [25] Cholinesterase inhibitors in the treatment of Alzheimer's disease and related dementias
    Masterman, D
    CLINICS IN GERIATRIC MEDICINE, 2004, 20 (01) : 59 - +
  • [26] Editorial: Methods and applications in Alzheimer's disease and related dementias
    Yogi, Alvaro
    Grosso, Carlos Ayala
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
  • [28] The Broad Range of Research in Alzheimer’s Disease and Related Dementias
    Steven T. DeKosky
    Ranjan Duara
    Neurotherapeutics, 2022, 19 : 1 - 7
  • [29] Treatment and care strategies for Alzheimer's disease and related dementias
    Foerstl, H.
    NERVENARZT, 2008, 79 (05): : 617 - 628
  • [30] Alzheimer's disease and related dementias: important policy issues
    Stone, RI
    AGING & MENTAL HEALTH, 2001, 5 : S146 - S148